Palvella Therapeutics (PVLA) FY2025 10-K Risk Factors: 82 New, 95 Dropped

What the changes say

Palvella Therapeutics faces significant financial risks advancing QTORIN rapamycin for rare skin diseases through clinical trials without approved commercial products.

What changed since the prior 10-K

New

New
Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs
We expect to incur significant operating losses and rising expenses as we advance QTORIN rapamycin and other candidates and operate as a public company.
New
Research and Development Expenses
Our research and development expenses consist primarily of clinical production materials, personnel, vendor fees for trials, consultant agreements, and regulatory compliance.
New
allocated overhead, including rent, equipment and information technology costs
We expense research and development costs as incurred and record nonrefundable advance payments for goods and services as prepaid expenses until utilized.
New
Our indirect research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs to identify and develop product candidates
We do not currently track indirect research and development expenses by program and expect these costs to rise as we advance late-stage trials.
New
A change in the outcome of any of these factors with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate
Unsuccessful preclinical studies, clinical trials, or unexpected FDA requirements would significantly alter the costs and timing of developing our product candidates.
New
General and Administrative Expenses
General and administrative expenses consist primarily of personnel costs and professional fees for legal, intellectual property, IT, and financial services.
New
professional fees for legal, intellectual property, information technology, financial, human resources, consulting, audit and accounting services not otherwise included in research and development expenses
General and administrative expenses will increase due to organizational growth, public company costs, and potential sales and marketing operations.
New
Comparison of the Years Ended December 31, 2025 and 2024
For the year ended December 31, 2025, research and development expenses were $22,841,000 and general and administrative expenses were $15,761,000, resulting in a $38,602,000 operating loss.
New
Total Other (Expense) Income
Total other expense for the year ended December 31, 2025 was $3,100,000, driven largely by royalty agreement interest.
New
Interest (expense) income – royalty agreement
We recorded $5,818,000 in interest expense related to the change in fair value of our royalty agreement liability for 2025.
New
Interest expense - convertible notes payable
Convertible notes automatically converted into common stock or prefunded warrants upon the closing of the PIPE Financing, resulting in no interest expense for 2025.
New
Fair value adjustments on derivative liabilities – royalty agreement
We recorded a non-cash loss of $400,000 in 2025 related to fair value adjustments on derivative liabilities under the Amended Ligand Agreement.
New
Fair value adjustments on convertible notes payable
New
Fair value adjustments on derivative liabilities – contingent value right liability
New
Other income – German R&D tax credit receivable
New
February 2026 Public Offering
New
Future Funding Requirements
New
Net cash used in operating activities
New
For the year ended December 31, 2025, net cash used in financing activities was $0.7 million, consisting primarily of payments of transaction costs incurred in connection with the Business Combination and proceeds from the exercise of options
New
Critical Accounting Policies and Significant Judgments and Estimates
New
Research and Development Expenses and Accruals
New
assumptions that include the estimated size of the addressable patient population and the anticipated pricing of the Company’s products. These assumptions are subject to significant variability, and are thus subject to significant uncertainty
New
Recently Adopted Accounting Pronouncements
New
Evaluation of Disclosure Controls and Procedures
New
Management’s Report on Internal Control over Financial Reporting
New
Changes in Internal Control over Financial Reporting
New
(b) Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
New
The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2025
New
It em 11. Executive Compensation
New
It em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
New
It em 13. Certain Relationships and Related Transactions, and Director Independence
New
Ite m 14. Principal Accounting Fees and Services
New
Notes to Consolidated Financial Statements
New
Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)
New
Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6)
New
President and Chief Executive Officer
New
Opinion on the Financial Statements
New
Description of the Matter
New
based on changes in the probability-adjusted cash flow estimates of the Company’s potential future royalty payments under the Ligand Agreement
New
How We Addressed the Matter in Our Audit
New
LIABILITIES AND STOCKHOLDERS' EQUITY
New
Commitments and contingencies (Note 9)
New
Costs to issue convertible notes
New
Foreign Currency Translation
New
Concentration of Credit Risk and Other Risks and Uncertainties
New
Comprehensive Loss and Accumulated Other Comprehensive (Loss) Income
New
Cash and Cash Equivalents
New
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques
New
Research and development costs are charged to expense as incurred. Research and development expenses include, among other costs, salaries and benefits of scientific personnel and the external cost of producing and testing the clinical material for clinical trials
New
German Research and Development Tax Credit Receivable
New
Related Party Transactions
New
Recently Adopted Accounting Standards
New
Recently Issued (Not Yet Adopted) Accounting Standards
New
fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is still evaluating the impacts the ASU has on its consolidated financial statements
New
All of the then outstanding shares of Legacy Palvella common stock were converted into 1,770,167 shares of the Company’s common stock, based on the exchange ratio of approximately 0.309469242 (the “Exchange Ratio”)
New
All outstanding 15,617 shares of Pieris preferred stock remained outstanding through the completion of the Reverse Merger, with no changes to their terms and conditions
New
All of the then outstanding stock options of Legacy Palvella were exchanged for options to purchase common stock of the Company, subject to the Exchange Ratio
New
The Company designated a majority of the Company’s board of directors and maintained a majority of the composition of management
New
Contingent Value Rights Agreement
New
Assets and Liabilities Measured at Fair Value on a Recurring Basis
New
Assumptions Used in Determining Fair Value of Derivative Liabilities
New
Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis
New
The derivative liabilities – contingent value rights is classified as short term on the Company’s consolidated balance sheets according to the estimated timing of the occurrence of the potential payments
New
Ligand Development Funding Agreement
New
Note 6. Accrued Expenses and Other Current Liabilities
New
Note 7. Convertible Notes Payable
New
Note 8. Convertible Preferred Stock
New
Note 9. Stockholders’ Equity
New
Each share of the Company’s common stock is entitled to one vote and all shares rank equally as to voting and other matters. Dividends may be declared and paid on the common stock from funds legally available therefor, if, as and when determined by the Board of Directors
New
For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of State
New
Note 10. Equity Incentive Plans
New
As of December 31, 2025, 2,322,854 shares of Common Stock were issued under the 2024 Plan
New
The aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2025 was $ 131.2 million and $ 43.4 million , respectively
New
As of December 31, 2025, there was approximately $ 30.1 million of unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a remaining weighted-average service period of 2.89 years
New
Note 11. Operating Lease Commitments
New
The Company has recorded right-of-use assets of $ 0.6 million and lease liabilities of $ 0.6 million for its operating lease on the consolidated balance sheet as of December 31, 2025
New
Effective income tax rate
New
Note 13. Commitments and Contingencies
New
Note 14. Segment Information
New
Chief Executive Officer (CEO). The CODM views the Company’s operations as a single operating segment which is the business of discovering and developing products for individuals with serious and rare skin diseases
New
General and Administrative Expenses : These expenses include costs associated with the overall administration and management of the Company, including salaries and benefits for administrative personnel, professional service fees (e.g., accounting and legal services) and other office expenses
New
In January 2026, the Company paid out approximately $ 2.0 million to holders of C VRs in accordance with the CVR Agreement entered into immediately prior to closing of the Merger on December 13, 2024

Dropped

DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
We have historically incurred significant operating losses and anticipate that we will continue to incur significant operating losses for at least the next several years. We may never achieve or maintain profitability
History of operating losses and accumulated deficit of $93.7 million.
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
seek to identify and develop or in-license additional product candidates;
Need to identify additional product candidates and expand infrastructure.
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
We have never generated revenue from product sales and may never achieve or maintain profitability
Never generated revenue from product sales and may not achieve profitability.
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
Our limited operating history may make it difficult to evaluate our business to date and our future viability
Late clinical-stage biopharmaceutical company with a limited operating history.
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans
Future capital requirements depend on scope and progress of trials.
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
Our development funding agreement with Ligand obligates us to make certain milestone payments, some of which will be triggered prior to our commercialization of any of our product candidates
DroppedRisks Related to Our Limited Operating History, Financial Position and Capital Requirements
Our ability to utilize our net operating loss (“NOL”) carryforwards and certain other tax attributes may be limited
Ligand development funding agreement obligates $5.0 million in milestone payments.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Clinical drug development is a lengthy, complex and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates
Ability to utilize net operating loss carryforwards may be limited.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
3 clinical trials of QTORIN rapamycin in patients with pachyonychia congenita failed to meet their respective primary endpoints
Lengthy, complex, and expensive clinical drug development process.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate
Three clinical trials of QTORIN rapamycin in pachyonychia congenita failed.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin, which is in later stages of development than our other product candidates
Risk of insufficient or inadequate product candidate supply or quality.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
the ability to raise any additional required capital on acceptable terms, or at all;
Substantial dependence on QTORIN rapamycin for rare genetic skin diseases.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;
Capital raising ability and third-party contractor performance dependencies.
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
our ability to establish and enforce intellectual property rights to our product candidates, any future product candidates, and commercial products, if any
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would adversely impact our potential to generate revenue, our business and our results of operations
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
the potential for approval policies or regulations of the FDA or the equivalent non-U.S. regulatory authorities to significantly change in a manner rendering our data insufficient for approval or invalidated
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
commented that a placebo-controlled trial or additional trials assessing different clinical endpoints may be required to assess the efficacy of QTORIN rapamycin for the treatment of microcystic LM
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Our lead product candidates are based on our QTORIN platform, which is highly dependent on the successful development of this novel and unproven technology
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We may find it difficult to enroll subjects in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We may be unable to obtain Orphan Drug Designation for certain of our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We are targeting rare genetic skin diseases, and the small patient populations associated with such diseases present additional risks with respect to clinical development, regulatory approvals and commercialization of product candidates
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
we expect to face challenges with respect to patient enrollment in our clinical trials, as described above;
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA’s prior findings regarding the safety and efficacy of rapamycin. If we are not able to pursue this strategy, we may be delayed in receiving regulatory authority approval
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
The validity, scope and enforceability of any patents that we may list in the Orange Book that cover QTORIN rapamycin, if approved by the FDA for any indication, can be challenged by competitors
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, which could materially adversely affect our business, financial condition, results of operations and prospects
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Interim, top-line or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, if granted, which would reduce or eliminate our potential return on investment for those product candidates
DroppedRisks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates
Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenue, if any
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
Even if QTORIN rapamycin or any future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
the clinical indications for which a product candidate is approved;
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
publicity relating to our product candidates or those of our competitors;
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
utilization controls imposed by third-party payors, such as prior authorizations and step edits
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
Our estimated market opportunities for our product candidates are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
The size of the markets for our product candidates has not been established and may be smaller than we estimate
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
If we are unable to achieve and maintain coverage and adequate levels of reimbursement for any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, our commercial success may be severely hindered
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
different regulatory requirements for approval of drugs in foreign countries;
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
unexpected changes in tariffs, trade barriers and regulatory requirements;
DroppedRisks Related to Commercialization of Our Product Candidates, if Approved
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
DroppedRisks Related to Our Business and Operations
We will need to increase the size of our organization, and we may experience difficulties in executing our growth strategy and managing any growth, including with respect to any acquired businesses, therapeutic candidates or technologies
DroppedRisks Related to Our Business and Operations
manage our third-party supply and manufacturing operations effectively and in a cost-effective manner, while increasing production capabilities for our current product candidates to commercial levels
DroppedRisks Related to Our Business and Operations
If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop our current and any future product candidates, commercialize our product candidates or otherwise implement our business plan
DroppedRisks Related to Our Business and Operations
We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for our product candidates and may have to limit our commercialization if we obtain regulatory approval
DroppedRisks Related to Our Business and Operations
initiation of investigations, and enforcement actions by regulators; and product recalls, withdrawals, revocation of approvals, or labeling, marketing or promotional restrictions
DroppedRisks Related to Our Business and Operations
Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations
DroppedRisks Related to Our Business and Operations
If we or our third-party contractors fail to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
warning or untitled letters, Form 483s, or holds on clinical trials;
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
fines, injunctions or the imposition of civil or criminal penalties
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
We will be subject to healthcare laws and regulations relating to our business and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
Healthcare reform measures may increase the difficulty and cost for us to successfully commercialize our product and product candidates, if approved, and affect the prices we may obtain
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
Any product candidates for which we are able to obtain regulatory approval in the future may become subject to unfavorable pricing regulations, third-party payor coverage and reimbursement policies, or healthcare reform initiatives
DroppedRisks Related to Healthcare Laws and Other Legal Compliance Matters
materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, financial condition, results of operations and prospects
DroppedRisks Related to Our Reliance on Third Parties
the risk that our CMOs face financial difficulties or declare bankruptcy; and
DroppedRisks Related to Our Reliance on Third Parties
reliance on the third party for product development, analytical testing and data generation to support regulatory applications;
DroppedRisks Related to Our Reliance on Third Parties
carrier disruptions or increased costs that are beyond our control
DroppedRisks Related to Our Reliance on Third Parties
We acquire the pumps we intend to use to dispense our QTORIN rapamycin, if approved, from a sole source supplier. If we experience an interruption in supply from this supplier, our business may be harmed
DroppedRisks Related to Our Reliance on Third Parties
Our third parties may also have relationships with other commercial entities, some of which may compete with us. In some cases, these third parties could terminate their agreements with us without cause
DroppedRisks Related to Our Reliance on Third Parties
We intend to explore strategic collaborations with third parties for the development or commercialization of our product candidates, which collaborations may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates
DroppedRisks Related to Our Reliance on Third Parties
to independently commercialize this product candidate in the United States, we may selectively seek collaborators to commercialize our products outside of the U.S. market
DroppedRisks Related to Our Reliance on Third Parties
collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates
DroppedRisks Related to Intellectual Property
We may not be able to obtain, maintain or enforce patent rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us
DroppedRisks Related to Intellectual Property
Patent terms may be inadequate to protect our competitive position and if we do not obtain additional patent protection by issuing additional patents with longer patent terms for our product candidates, our business may be materially harmed
DroppedRisks Related to Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
DroppedRisks Related to Intellectual Property
Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
DroppedRisks Related to Intellectual Property
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
DroppedRisks Related to Intellectual Property
Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
DroppedRisks Related to Intellectual Property
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
DroppedRisks Related to Intellectual Property
We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license
DroppedRisks Related to Intellectual Property
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
DroppedRisks Related to Intellectual Property
We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property
DroppedRisks Related to Intellectual Property
We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
DroppedRisks Related to Intellectual Property
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business
DroppedRisks Related to Intellectual Property
We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
DroppedRisks Related to Intellectual Property
Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors
DroppedRisks Related to Intellectual Property
our right to sublicense patent and other rights to third parties;
DroppedRisks Related to Intellectual Property
the priority of invention of patented technology
DroppedRisks Related to Intellectual Property
If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary or useful for developing and protecting our product candidates
DroppedRisks Related to Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
DroppedRisks Related to Intellectual Property
We have not yet registered trademarks for a commercial trade name for our lead candidates in the United States or foreign jurisdictions and failure to secure such registrations could adversely affect our business
DroppedRisks Related to Intellectual Property
Intellectual property rights do not necessarily address all potential threats to our competitive advantage
DroppedRisks Related to Ownership of Our Common Stock
The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially
DroppedRisks Related to Ownership of Our Common Stock
the other factors described in this “Risk Factors” section
DroppedRisks Related to Ownership of Our Common Stock
Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
DroppedRisks Related to Ownership of Our Common Stock
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
DroppedRisks Related to Ownership of Our Common Stock
We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment
DroppedRisks Related to Ownership of Our Common Stock
Because we do not anticipate paying any cash dividends on our share capital in the foreseeable future, capital appreciation, if any, will be your sole source of gain
DroppedRisks Related to Ownership of Our Common Stock
Provisions in our charter and bylaws, as well as provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management
DroppedRisks Related to Ownership of Our Common Stock
certain limitations on convening special stockholder meetings and the prohibition of stockholder action by written consent; and
DroppedRisks Related to Ownership of Our Common Stock
Our articles of incorporation contain exclusive forum provisions, which may limit a stockholder’s ability to bring a claim in a judicial forum such stockholder finds favorable and may discourage lawsuits with respect to such claims

Reworded

100% rewritten
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio
Changed from discussing general financing availability and dilution risks to focusing on potential changes in operating plans and capital requirements for QTORIN rapamycin.

All 83 risk factors

Headings as the filing states them, in filing order.

Other

01Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costsNew
02Research and Development ExpensesNew
03allocated overhead, including rent, equipment and information technology costsNew
04Our indirect research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs to identify and develop product candidatesNew
05A change in the outcome of any of these factors with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidateNew
06General and Administrative ExpensesNew
07professional fees for legal, intellectual property, information technology, financial, human resources, consulting, audit and accounting services not otherwise included in research and development expensesNew
08Comparison of the Years Ended December 31, 2025 and 2024New
09Total Other (Expense) IncomeNew
10Interest (expense) income – royalty agreementNew
11Interest expense - convertible notes payableNew
12Fair value adjustments on derivative liabilities – royalty agreementNew
13Fair value adjustments on convertible notes payableNew
14Fair value adjustments on derivative liabilities – contingent value right liabilityNew
15Other income – German R&D tax credit receivableNew
16February 2026 Public OfferingNew
17Future Funding RequirementsNew
18the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio100% rewritten
19Net cash used in operating activitiesNew
20For the year ended December 31, 2025, net cash used in financing activities was $0.7 million, consisting primarily of payments of transaction costs incurred in connection with the Business Combination and proceeds from the exercise of optionsNew
21Critical Accounting Policies and Significant Judgments and EstimatesNew
22Research and Development Expenses and AccrualsNew
23assumptions that include the estimated size of the addressable patient population and the anticipated pricing of the Company’s products. These assumptions are subject to significant variability, and are thus subject to significant uncertaintyNew
24Recently Adopted Accounting PronouncementsNew
25Evaluation of Disclosure Controls and ProceduresNew
26Management’s Report on Internal Control over Financial ReportingNew
27Changes in Internal Control over Financial ReportingNew
28(b) Rule 10b5-1 and Non-Rule 10b5-1 Trading ArrangementsNew
29The information required by this item is incorporated by reference to our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2025New
30It em 11. Executive CompensationNew
31It em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder MattersNew
32It em 13. Certain Relationships and Related Transactions, and Director IndependenceNew
33Ite m 14. Principal Accounting Fees and ServicesNew
34Notes to Consolidated Financial StatementsNew
35Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)New
36Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6)New
37President and Chief Executive OfficerNew
38Opinion on the Financial StatementsNew
39Description of the MatterNew
40based on changes in the probability-adjusted cash flow estimates of the Company’s potential future royalty payments under the Ligand AgreementNew
41How We Addressed the Matter in Our AuditNew
42LIABILITIES AND STOCKHOLDERS' EQUITYNew
43Commitments and contingencies (Note 9)New
44Costs to issue convertible notesNew
45Foreign Currency TranslationNew
46Concentration of Credit Risk and Other Risks and UncertaintiesNew
47Comprehensive Loss and Accumulated Other Comprehensive (Loss) IncomeNew
48Cash and Cash EquivalentsNew
49Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniquesNew
50Research and development costs are charged to expense as incurred. Research and development expenses include, among other costs, salaries and benefits of scientific personnel and the external cost of producing and testing the clinical material for clinical trialsNew
51German Research and Development Tax Credit ReceivableNew
52Related Party TransactionsNew
53Recently Adopted Accounting StandardsNew
54Recently Issued (Not Yet Adopted) Accounting StandardsNew
55fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is still evaluating the impacts the ASU has on its consolidated financial statementsNew
56All of the then outstanding shares of Legacy Palvella common stock were converted into 1,770,167 shares of the Company’s common stock, based on the exchange ratio of approximately 0.309469242 (the “Exchange Ratio”)New
57All outstanding 15,617 shares of Pieris preferred stock remained outstanding through the completion of the Reverse Merger, with no changes to their terms and conditionsNew
58All of the then outstanding stock options of Legacy Palvella were exchanged for options to purchase common stock of the Company, subject to the Exchange RatioNew
59The Company designated a majority of the Company’s board of directors and maintained a majority of the composition of managementNew
60Contingent Value Rights AgreementNew
61Assets and Liabilities Measured at Fair Value on a Recurring BasisNew
62Assumptions Used in Determining Fair Value of Derivative LiabilitiesNew
63Changes in Level 3 Liabilities Measured at Fair Value on a Recurring BasisNew
64The derivative liabilities – contingent value rights is classified as short term on the Company’s consolidated balance sheets according to the estimated timing of the occurrence of the potential paymentsNew
65Ligand Development Funding AgreementNew
66Note 6. Accrued Expenses and Other Current LiabilitiesNew
67Note 7. Convertible Notes PayableNew
68Note 8. Convertible Preferred StockNew
69Note 9. Stockholders’ EquityNew
70Each share of the Company’s common stock is entitled to one vote and all shares rank equally as to voting and other matters. Dividends may be declared and paid on the common stock from funds legally available therefor, if, as and when determined by the Board of DirectorsNew
71For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of StateNew
72Note 10. Equity Incentive PlansNew
73As of December 31, 2025, 2,322,854 shares of Common Stock were issued under the 2024 PlanNew
74The aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2025 was $ 131.2 million and $ 43.4 million , respectivelyNew
75As of December 31, 2025, there was approximately $ 30.1 million of unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a remaining weighted-average service period of 2.89 yearsNew
76Note 11. Operating Lease CommitmentsNew
77The Company has recorded right-of-use assets of $ 0.6 million and lease liabilities of $ 0.6 million for its operating lease on the consolidated balance sheet as of December 31, 2025New
78Effective income tax rateNew
79Note 13. Commitments and ContingenciesNew
80Note 14. Segment InformationNew
81Chief Executive Officer (CEO). The CODM views the Company’s operations as a single operating segment which is the business of discovering and developing products for individuals with serious and rare skin diseasesNew
82General and Administrative Expenses : These expenses include costs associated with the overall administration and management of the Company, including salaries and benefits for administrative personnel, professional service fees (e.g., accounting and legal services) and other office expensesNew
83In January 2026, the Company paid out approximately $ 2.0 million to holders of C VRs in accordance with the CVR Agreement entered into immediately prior to closing of the Merger on December 13, 2024New

Other Palvella Therapeutics 10-Ks

FY2024 10-K risk factors
96 risks
Palvella is an early-stage biopharmaceutical company with zero product revenue and substantial historical operating losses.
Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.